|
|
Phase I Study of Recombinant Vaccinia TRICOM Vaccine in Patients With Metastatic Melanoma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Trial Contact Information Registry Information
Alternate Title
Vaccine Therapy in Treating Patients With Metastatic Melanoma
Basic Trial Information
Phase | Type | Status | Age | Protocol IDs |
---|
Phase I | Treatment | Closed | Over 18 | CPMC-IRB-14387 AECM-01-003, NCI-3353, NCT00022568, 3353 |
Objectives - Determine the maximum tolerated dose of recombinant vaccinia-TRICOM vaccine in patients with metastatic melanoma.
- Determine the clinical toxic effects of this vaccine in these patients.
- Determine the safety of this vaccine in these patients.
- Determine the clinical response of these patients to this vaccine.
- Determine evidence of host anti-melanoma immune reactivity in these patients after treatment with this vaccine.
Entry Criteria Disease Characteristics:
- Histologically confirmed metastatic non-resectable cutaneous,
subcutaneous, or
lymph node malignant melanoma
- Lesion(s) must be accessible to percutaneous injection
- Measurable lesion(s)
- Previously treated brain metastases with no evidence of disease or edema
on MRI or CT scan allowed
- At least 6 weeks since prior definitive therapy
(surgery or radiotherapy)
- No untreated or edematous metastatic brain lesions or leptomeningeal
disease
- No ascites or pleural effusions
Prior/Concurrent Therapy:
Biologic therapy: - Prior vaccinia immunization required (e.g., smallpox
vaccination)
- More than 8 weeks since prior immunotherapy and
recovered
- No prior therapy with live vaccinia virus vector
Chemotherapy: - More than 4 weeks since prior chemotherapy and
recovered
Endocrine therapy: - At least 4 weeks since prior systemic
corticosteroids
- No concurrent systemic corticosteroids
- No concurrent steroids
Radiotherapy: - See Disease Characteristics
- More than 2 weeks since prior radiotherapy and
recovered
Surgery: - See Disease Characteristics
- More than 4 weeks since prior surgery for primary tumor or
metastatic lesions and recovered
Other: - No concurrent immunosuppressive drugs
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - WBC at least 3,000/mm3
- Platelet count at least 100,000/mm3
- Absolute granulocyte count at least 3,000/mm3
- Hemoglobin at least 10 g/dL
Hepatic: - Direct bilirubin no greater than 1.5 mg/dL
- Transaminases no greater than 2 times upper limit of normal
(ULN)
- Alkaline phosphatase no greater than 2 times ULN
- No severe coagulation disorder with PT/PTT greater than 2
times normal (without anticoagulation medications)
- No hepatic insufficiency
- No alcoholic cirrhosis
Renal: - Creatinine no greater than 2.0 mg/dL
OR - Creatinine clearance at least 60 mL/min
- No renal insufficiency
Cardiovascular: - No congestive heart failure
- No serious cardiac arrhythmias
- No evidence of recent prior myocardial infarction on
EKG
- No clinical coronary artery disease
Pulmonary: - No chronic obstructive pulmonary disease
Immunologic: - No prior eczema
- HIV negative
- No immunocompromising conditions, (e.g., active autoimmune
disease, leukemia, lymphoma, skin diseases, or open wounds)
- No clinical or laboratory evidence of an underlying
immunosuppressive disorder
- No active or chronic infections
- No significant allergy or hypersensitivity to eggs
Other: - No active seizure disorders
- No other malignancy within the past 2 years except stage I
cervical cancer or basal cell skin cancer, provided the tumor has been
successfully treated and patient is currently disease free
- No evidence of bone marrow toxicity
- No other concurrent medical illness that would preclude
study
- No other contraindications to vaccinia virus
administration
- No encephalitis
- Must be able to avoid close contact with children under 3
years of age; pregnant women; individuals with prior or active eczema or
other open skin conditions; or immunosuppressed individuals for 7-10 days after each vaccination
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
Expected Enrollment A total of 12-18 patients will be accrued for this study within 6-12 months. Outline This is a dose-escalation study. Patients receive recombinant vaccinia-TRICOM vaccine once every 4 weeks
for a total of 3 vaccinations. Patients with stable or responding disease may
receive an additional course of vaccinations. Cohorts of 3-6 patients receive escalating doses of recombinant
vaccinia-TRICOM vaccine until the maximum tolerated dose (MTD) is determined.
The MTD is defined as the dose preceding that at which 2 of 6 patients
experience dose-limiting toxicity. Quality of life is assessed at baseline, at each vaccine administration,
and at study completion. Patients are followed at 3 months.
Trial Contact Information
Trial Lead Organizations Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center | | | Howard Kaufman, MD, Protocol chair(Contact information may not be current) | | | |
Registry Information | | Official Title | | A Phase I Trial of Intra Lesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma | | Trial Start Date | | 2001-08-27 | | Registered in ClinicalTrials.gov | | NCT00022568 | | Date Submitted to PDQ | | 2001-06-27 | | Information Last Verified | | 2003-12-08 | | NCI Grant/Contract Number | | P30-CA13696 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
|